Cargando…

Epigenetic modification and BRAF gene mutation in thyroid carcinoma

Thyroid cancer remains the most prevailing endocrine malignancy, and a progressively increasing incidence rate has been observed in recent years, with 95% of thyroid cancer represented by differentiated thyroid carcinomas. The genetics and epigenetics of thyroid cancer are gradually increasing, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Guo, Chen, Juan, Zhou, Jun, Xiao, Shuai, Zeng, Weihong, Xia, Jiliang, Zeng, Xi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684614/ https://www.ncbi.nlm.nih.gov/pubmed/34923978 http://dx.doi.org/10.1186/s12935-021-02405-w

Ejemplares similares

Association analysis and the clinical significance of BRAF gene mutations and ultrasound features in papillary thyroid carcinoma
por: Liu, Ying, et al.
Publicado: (2019)

BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients
por: Jin, Langping, et al.
Publicado: (2016)

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
por: Kim, Woon Won, et al.
Publicado: (2018)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases
por: Fakhruddin, Najla, et al.
Publicado: (2017)

BRAF in Papillary Thyroid Carcinoma
por: Lanzilotta, Salvatore Giovanni, et al.
Publicado: (2007)

High BRAF(V600E) mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules
por: Li, Xing-Jia, et al.
Publicado: (2019)

Phospholipase C delta 1 inhibits WNT/β‐catenin and EGFR-FAK-ERK signaling and is disrupted by promoter CpG methylation in renal cell carcinoma
por: Xie, Jianlian, et al.
Publicado: (2023)

Anticancer and Anti-Inflammatory Mechanisms of NOSH-Aspirin and Its Biological Effects
por: Zhou, Jun, et al.
Publicado: (2022)

BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma
por: Henke, Lauren E, et al.
Publicado: (2015)

Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis
por: Song, Young Shin, et al.
Publicado: (2017)

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates
por: Al-Salam, Suhail, et al.
Publicado: (2020)

BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma
por: Pongsapich, Warut, et al.
Publicado: (2019)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

Multicentric occurrence of multiple papillary thyroid carcinomas –HUMARA and BRAF mutation analysis
por: Nakazawa, Tadao, et al.
Publicado: (2015)

Effect of BRAF mutational status on expression profiles in conventional papillary thyroid carcinomas
por: Schulten, Hans-Juergen, et al.
Publicado: (2015)

Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations
por: Hahn, Soo Yeon, et al.
Publicado: (2017)

The Significance of TROP2 Expression in Predicting BRAF Mutations in Papillary Thyroid Carcinoma
por: Kong, Joon Seog, et al.
Publicado: (2018)

The Impact of BRAF Mutation on the Recurrence of Papillary Thyroid Carcinoma: A Meta-Analysis
por: Li, Xin, et al.
Publicado: (2020)

SUN-LB78 Hyperfunctioning Papillary Thyroid Carcinoma With a BRAF Mutation
por: Shinkai, Shinsuke, et al.
Publicado: (2020)

Preoperative BRAF(V600E) mutation detection in thyroid carcinoma by immunocytochemistry
por: Swan, Kristine Zøylner, et al.
Publicado: (2022)

Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
por: Li, Qian, et al.
Publicado: (2017)

BRAF Testing in Multifocal Papillary Thyroid Carcinoma
por: Kimbrell, Hillary Z., et al.
Publicado: (2015)

Osteopontin expression in papillary thyroid carcinoma and its relationship with the BRAF mutation and tumor characteristics
por: Kang, Kyung Ho
Publicado: (2013)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
por: Heriyanto, Didik Setyo, et al.
Publicado: (2022)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

Expression of miRNAs in Papillary Thyroid Carcinomas Is Associated with BRAF Mutation and Clinicopathological Features in Chinese Patients
por: Sun, Yun, et al.
Publicado: (2013)

Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto’s Thyroiditis
por: Zhang, Qin, et al.
Publicado: (2017)

Assessment of epigenetic alterations in early colorectal lesions containing BRAF mutations
por: Sawada, Takeshi, et al.
Publicado: (2016)

Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
por: Bui Dang Minh, Tri, et al.
Publicado: (2023)

Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutation
por: Kikuchi, Yasuko, et al.
Publicado: (2013)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Prognostic Significance of COX-2 Overexpression in BRAF-Mutated Middle Eastern Papillary Thyroid Carcinoma
por: Parvathareddy, Sandeep Kumar, et al.
Publicado: (2020)

Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma
por: Barreno, Luis Rene Quiroa, et al.
Publicado: (2020)

BRAF mutations in thyroid tumors from an ethnically diverse group
por: Schulten, Hans-Juergen, et al.
Publicado: (2012)

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype
por: Hanly, Elyse K, et al.
Publicado: (2014)

Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment
por: Khatami, Fatemeh, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_omlq5302lqdkmhq5ibh9l83t4r